title: Response to rituximab in 3 children with opsoclonus-myoclonus syndrome resistant to conventional treatments.
abstract: We report the 1 year follow-up of 3 children affected by non-paraneoplastic Opsoclonus-Myoclonus Syndrome (OMS) resistant to conventional therapies (steroids, ACTH and intravenous immunoglobulins) who were treated with an anti CD20 monoclonal antibody (rituximab). Treatment response was recorded on the basis of an international score at 0, 3, 6, 9 and 12 months. Despite the long disease duration and the numerous previously administered treatments, all patients underwent rapid and persistent neurological recovery following rituximab administration, thus suggesting a potential role of this drug even in pre-treated patients.
authors: Department of Paediatric Haematology and Oncology, G. Gaslini Institute, Genoa, Italy.
authors: Teresa
authors: T
authors: Battaglia
authors: Elisa
authors: E
authors: De Grandis
authors: Marisol
authors: M
authors: Mirabelli-Badenier
authors: Luca
authors: L
authors: Boeri
authors: Guido
authors: G
authors: Morcaldi
authors: Paola
authors: P
authors: Barabino
authors: Chiara
authors: C
authors: Intra
authors: Francesca
authors: F
authors: Naselli
authors: Vito
authors: V
authors: Pistoia
authors: Edvige
authors: E
authors: Veneselli
authors: Massimo
authors: M
authors: Conte
mesh_terms: D000324:Adrenocorticotropic Hormone / Q000627:therapeutic use; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D058846:Antibodies, Monoclonal, Murine-Derived / Q000627:therapeutic use*; D001259:Ataxia / Q000188:drug therapy / Q000209:etiology; D002653:Child Behavior Disorders / Q000209:etiology / Q000523:psychology; D003907:Dexamethasone / Q000627:therapeutic use; D004351:Drug Resistance; D004569:Electroencephalography; D020233:Gait Disorders, Neurologic / Q000188:drug therapy / Q000209:etiology; D006801:Humans; D016756:Immunoglobulins, Intravenous / Q000627:therapeutic use; D007223:Infant; D008279:Magnetic Resonance Imaging; D008297:Male; D053578:Opsoclonus-Myoclonus Syndrome / Q000188:drug therapy*; D011241:Prednisone / Q000627:therapeutic use; D000069283:Rituximab; D013064:Speech Disorders / Q000188:drug therapy / Q000209:etiology; D016896:Treatment Outcome; D014202:Tremor / Q000188:drug therapy / Q000209:etiology; D014777:Virus Diseases / Q000150:complications
chemical_list: D000893:Anti-Inflammatory Agents; D058846:Antibodies, Monoclonal, Murine-Derived; D016756:Immunoglobulins, Intravenous; D000069283:Rituximab; D003907:Dexamethasone; D000324:Adrenocorticotropic Hormone; D011241:Prednisone